136 related articles for article (PubMed ID: 9174681)
1. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
Bergström M; Westerberg G; Németh G; Traut M; Gross G; Greger G; Müller-Peltzer H; Safer A; Eckernäs SA; Grahnér A; Långström B
Eur J Clin Pharmacol; 1997; 52(2):121-8. PubMed ID: 9174681
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.
Ginovart N; Meyer JH; Boovariwala A; Hussey D; Rabiner EA; Houle S; Wilson AA
J Cereb Blood Flow Metab; 2006 Mar; 26(3):330-44. PubMed ID: 16079787
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
Sacher J; Houle S; Parkes J; Rusjan P; Sagrati S; Wilson AA; Meyer JH
J Psychiatry Neurosci; 2011 Nov; 36(6):375-82. PubMed ID: 21463543
[TBL] [Abstract][Full Text] [Related]
4. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies.
Bergström M; Westerberg G; Långström B
Nucl Med Biol; 1997 May; 24(4):287-93. PubMed ID: 9257326
[TBL] [Abstract][Full Text] [Related]
5. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
Wiesel FA; Raaflaub J; Kettler R
Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
8. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
10. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.
Cesura AM; Kettler R; Imhof R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S15-6. PubMed ID: 1546132
[TBL] [Abstract][Full Text] [Related]
11. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
Da Prada M; Kettler R; Keller HH; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():103-5. PubMed ID: 2248059
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
[TBL] [Abstract][Full Text] [Related]
14. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
[TBL] [Abstract][Full Text] [Related]
15. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
[TBL] [Abstract][Full Text] [Related]
16. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
Dingemanse J; Korn A; Pfefen JP; Güntert TW
Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
[TBL] [Abstract][Full Text] [Related]
17. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
18. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
[TBL] [Abstract][Full Text] [Related]
20. Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [11C]harmine and [11C]raclopride.
Jensen SB; Olsen AK; Pedersen K; Cumming P
Synapse; 2006 Jun; 59(7):427-34. PubMed ID: 16485265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
